North American Scientific Scheduled for Nasdaq Listing Hearing on May 22, 2008

  
    
  
  
    
      North American Scientific, Inc. (NASDAQ:NASI) today announced it 
      received a letter from The Nasdaq Stock Market (“Nasdaq”) 
      providing formal notice that the Nasdaq Listing Qualifications Panel 
      will consider the Company’s appeal of Nasdaq’s 
      delisting action at a hearing scheduled for May 22, 2008.
    
    
      The delisting action will be stayed pending the issuance of a written 
      determination by a Nasdaq Listing Qualifications Panel following the 
      hearing. The Company’s common stock will 
      remain quoted on The Nasdaq Capital Market pending the outcome of the 
      appeal.
    
    
      The Company is required to submit a plan to the Nasdaq Listing 
      Qualifications Panel by May 2, 2008. According to Nasdaq, historically 
      Panels have generally viewed a near-term reverse stock split as an 
      acceptable definitive plan to resolve a bid price deficiency. The Company’s 
      plan will include a one share for five share reverse stock split, 
      approved by its Board of Directors on February 15, 2008, to be voted 
      upon by its Stockholders. While the Company believes its plan will be 
      successful, there can be no assurances that a Nasdaq Listing 
      Qualifications Panel will grant the Company’s 
      request for continued listing on The Nasdaq Global Market.
    
    
      About North American Scientific
    
    
      North American Scientific is a leader in radiation therapy in the fight 
      against cancer. Its innovative products provide physicians with tools 
      for the treatment of various types of cancers. They include Prospera® 
      brachytherapy seeds and SurTRAK™ needles and 
      strands used primarily in the treatment of prostate cancer. In addition, 
      the Company has been gaining clinical experience with its first 
      generation ClearPath™ multi-channel catheter 
      breast brachytherapy devices in 2007, and intends to launch the second 
      generation devices in 2008. They are the only such devices approved for 
      both high dose and continuous release, or low dose, radiation 
      treatments. The devices are designed to provide flexible, precise dose 
      conformance and an innovative delivery system that is intended to offer 
      the more advanced form of brachytherapy for the treatment of breast 
      cancer. Please visit www.nasmedical.com 
      for more information.
    
    
      Statements included in this release that are not historical facts may 
      be considered forward-looking statements that are subject to a variety 
      of risks and uncertainties. There are a number of important factors that 
      could cause actual results to differ materially from those expressed in 
      any forward-looking statements made by the Company including, but not 
      limited to, the impact of competitive products and pricing, 
      technological changes, changes in relationships with strategic partners 
      and dependence upon strategic partners for the performance of critical 
      activities under collaborative agreements, the ability of the Company to 
      successfully directly market and sell its products, uncertainties 
      relating to patent protection and regulatory approval, the stable supply 
      of appropriate isotopes, research and development estimates, market 
      opportunities, risks associated with strategic opportunities or 
      acquisitions the Company may pursue and the risk factors included in the 
      Company’s filings with the Securities and 
      Exchange Commission. Any forward-looking statements contained in this 
      news release speak only as of the date of this release, and the Company 
      undertakes no obligation to revise or update any forward-looking 
      statements, whether as a result of new information, future results or 
      otherwise.